Roche Holding AG Basel American Depositary Shares (RHHBY)

BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

This biotech stock looks like a great candidate to buy on the admittedly steep dip.

They aren't the most prominent names in the GLP-1 space, but they are worth a second look.

They are fairly risky, but their potential upside is massive.

Want to put your money into global stocks that might be big winners from AI? These two low-cost ETFs offer international diversification.

There are good reasons to invest in Lilly and to hold off.

When buying international dividend stocks, diversification is likely the best bet.

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

These international stock ETFs from iShares and Vanguard are very different once you look under the surface.

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

These stocks are better bets to skyrocket than the much-hyped rocket stock.

The long-term thesis remains largely unchanged.

Teva has been building its comeback, and the latest studies on Austedo and Austedo XR will help further that momentum.

When buying international ETFs, owning more stocks in more countries might be a better bet.

Don't be too quick to give up on the industry.

The stock looks cheap, but appearances can be deceiving.

These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.

The company is riding an incredible tailwind.

AbbVie is making progress in this market, but it is still far behind the leader.

As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an industry often characterized by volatile "one-hit wonders" and aggressive M&A cycles, Regeneron has carved out a unique identity as a founder-led, R&D-centric powerhouse. Currently, [...]

In a move that signals a decisive pivot for the biotechnology giant, Biogen Inc. (NASDAQ: BIIB) announced on March 31, 2026, that it has entered into a definitive agreement to acquire Apellis Pharmaceuticals (NASDAQ: APLS) for approximately $5.6 billion. The acquisition, which centers on Apellis' pioneering therapies targeting the

In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded (patented) pharmaceutical imports. The announcement, timed to coincide with the first anniversary of "Liberation Day"—the administration's 2025

As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for GLP-1 receptor agonists and multi-pathway incretins, once estimated to be a two-horse race, is now the frontline of a

WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff on all imported patented pharmaceutical products. The aggressive trade measure is designed to force multinational drugmakers to shift production